Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403380 | 0.85 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MAPTHRH3 | |
| SCHEMBL3468707 | 0.85 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2MAPTHRH3 | |
| SCHEMBL24329835 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL3468713 | 0.81 | HRH3 (0.58) | NPC1RAB9ASMN1; SMN2MAPTHRH3 | |
| SCHEMBL333717 | 0.80 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL29293351 | 0.80 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL334720 | 0.80 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL14046555 | 0.80 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL3468742 | 0.79 | RAB9A (0.70) | NPC1RAB9ASMN1; SMN2MAPTHRH3 | |
| SCHEMBL3469017 | 0.79 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | claimed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NPC1 3350/4885RAB9A 3540/4885SMN1; SMN2 4655/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NPC1 3474/4885RAB9A 3387/4885SMN1; SMN2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.